Search

Recent news

Amprologix selected to pitch at the World Innovation…

October 2022 CSO Mat Upton joined 19 other start-ups that were selected from 700 applicants for a place at the…

Amprologix pitch at the BIOCOM/BEAM ALLIANCE AMR Conference,…

April 2022 Gordon Barker, Amprologix CEO was selected to present our innovative antibiotic development approach at the Start-ups Session (https://amr-conference.com/start-ups-amr-conference-pitching-session/).…

New collaboration with RefLab shows beneficial properties of…

January 2022 Amprologix and RefLab ApS (Copenhagen, Denmark) have collaborated on a project using an ex vivo human skin microdialysis model (below)…

Pre-clinical evaluation of epidermicin NI01 for nasal administration

November 2021 Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. Amprologix…

Amprologix engages corporate finance partners FRP for its…

We are delighted to be working with Adrian Gare and Alex Starling at FRP, who have a great track record…

News categories

News articles

10 October 2022
Amprologix selected to pitch at the World Innovation Summit for Health (WISH 2022), Doha, Qatar

October 2022 CSO Mat Upton joined 19 other start-ups that were selected from 700 applicants for a place at the Qatar Foundation WISH meeting on 4-6th October 2022.

Read More
10 April 2022
Amprologix pitch at the BIOCOM/BEAM ALLIANCE AMR Conference, Basel, Switzerland

April 2022 Gordon Barker, Amprologix CEO was selected to present our innovative antibiotic development approach at the Start-ups Session (https://amr-conference.com/start-ups-amr-conference-pitching-session/). The session, sponsored by INCATE and partners, was watched by potential investors and funders and included SMEs developing novel therapies through to vaccines and diagnostics.

Read More
6 January 2022
New collaboration with RefLab shows beneficial properties of lead candidate epidermicin NI01 for topical skin therapy

January 2022 Amprologix and RefLab ApS (Copenhagen, Denmark) have collaborated on a project using an ex vivo human skin microdialysis model (below) to test pseudo-allergic reactions in the skin, without using animal models. 

Read More
6 November 2021
Pre-clinical evaluation of epidermicin NI01 for nasal administration

November 2021 Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. A formulation was developed for delivery of NI01 to the nasal cavity and this was shown to retain antimicrobial […]

Read More
21 August 2020
Understanding the mode of action of lead candidate

Amprologix CSO collaborates with Dr Max Ryadnov from the UK’s National Physical Laboratory, to publish new data on the novel mode of action of epidermicin NI01. Findings are reported in the August issue of iScience.

Read More
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram